Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.29 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Edwards Lifesciences Pops As Third-Quarter Beat Lifts 2025 Guidance
Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls. 
Via Investor's Business Daily
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
Thursday's session: most active stock in the S&P500 index
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily
Pfizer Addresses Proposal for Metsera
From Pfizer Inc.
Via Business Wire
Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years
Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth. 
Via The Motley Fool
2 High-Yield Stocks With Fresh Catalysts
Income investors can capture yields above 5% from companies executing business transformations. 
Via The Motley Fool
Topics Lawsuit
S&P 500 Healthcare Sector Navigates Mixed Market Waters on October 29, 2025
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
'I Still Can't Believe It's Around': Cramer Rips Plug Power
Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE) and Dow (DOW) discussed. Plug Power (PLUG) faces concerns over shareholder... 
Via Benzinga
Topics Stocks
1 S&P 500 Stock to Target This Week and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women. 
Via Benzinga
Topics Lawsuit
Why NeoGenomics (NEO) Stock Is Trading Up Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 
Via StockStory
Topics World Trade
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Dividend-Paying Drug Stocks to Buy at a Discount
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
Should You Buy Pfizer Stock Before Nov. 4?
The pharma giant is slated to report its latest quarterly numbers next week. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
Dow Jones Soars to New Record High Amidst Wave of Optimism, Signaling Robust Market Confidence
The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000
These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again. 
Via The Motley Fool
Topics Intellectual Property World Trade
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
Vertex appears to be by far the better buy right now. 
Via The Motley Fool
Topics Intellectual Property
3 Healthcare Stocks Paying the Highest Dividends of 2025
If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them. 
Via The Motley Fool
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story). 
Via The Motley Fool
Topics Government
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
Both companies are monsters in their industry and are poised to thrive. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter 
Via The Motley Fool
Topics Energy Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.